Three medications represent this progression: Semaglutide (single agonist, 15% average weight loss), Tirzepatide (dual agonist, 22.5% weight loss), and Retatrutide (triple agonist, 28.7% weight loss)
Weight Loss drug (Ozempic / Mounjaro lawsuit et al.) criteria to qualify for lawsuit | AS OF 07/09/2026: 1
Post- L-GSH supplementation, we found increased levels of IFN- in PBMCs ( Figure 5A ), increased levels of TNF- in plasma ( Figure 5C ) and PBMCs ( Figure 5D ), and increased levels of IL-2 in plasma ( Figure 5E ) and PBMCs ( Figure 5F ) when compared to before L-GSH supplementation
But what exactly is compounded tirzepatide, how does it work, and is it truly comparable to brand-name treatments
How else can the industry offset GLP-1s impact